Skip to content
Open access

CT-derived nested habitats score for preoperative IASLC grading in lung adenocarcinoma: cross-center validation and radiogenomic analysis

Nov 2026 · Frontiers in Molecular Biosciences · 0 citations · 66 references

Abstract

The 2020 International Association for the Study of Lung Cancer (IASLC) grading system integrates the predominant histologic pattern and the proportion of high-grade patterns, but preoperative CT assessment is limited by spatial averaging of heterogeneous tumor components. We aimed to develop a CT-derived nested habitats score (NHS) that recursively identifies grade-associated intratumoral CT subregions, evaluate its cross-center performance for preoperative IASLC grading, and explore its transcriptomic correlates. This retrospective two-center study included 650 patients with surgically resected lung adenocarcinoma. Center 1 formed the development cohort (n = 390); Center 2 was stratified 1:1 into validation (n = 130) and locked test (n = 130) cohorts, both from the same external institution. The prespecified primary task was pathologic IASLC Grade 1 versus Grade 2/3. NHS was generated using five-fold out-of-fold estimation in development data. Clinical-radiological, whole-tumor radiomics, NHS, and integrated models were compared, with algorithm selection confined to validation before one-time test evaluation. An independent TCGA-LUAD/TCIA CT-RNA cohort (n = 88) underwent exploratory WGCNA and Hallmark gene-set enrichment analysis. The development/validation/test cohorts contained 41/14/14 Grade 1, 293/101/96 Grade 2, and 56/15/20 Grade 3 tumors. The selected random-forest integrated model yielded AUCs of 0.871 (95% CI, 0.784–0.936) in validation and 0.866 (95% CI, 0.784–0.935) in testing. NHS alone yielded AUCs of 0.828 and 0.854, compared with 0.620 and 0.497 for the clinical-radiological model and 0.703 and 0.775 for whole-tumor radiomics. NHS accounted for 76.3% of mean absolute SHAP contribution; removing NHS reduced AUC by 0.251 (95% CI, 0.079–0.439) in validation and 0.369 (95% CI, 0.200–0.553) in testing. Brier scores for NHS and the integrated model (0.074–0.077) were below the non-informative reference (0.096), but calibration slopes exceeded 1, and decision curves showed no net benefit over treating all patients as Grade 2/3 at low-to-intermediate thresholds. Exploratory radiogenomics showed nominal NHS-associated coexpression modules and enrichment of WNT/beta-catenin, E2F, G2M-checkpoint, and immune-related programs. NHS discriminated IASLC Grade 1 from Grade 2/3 tumors, retained stable performance in two held-out cohorts from a second institution, and contributed most of the integrated model’s discrimination. The transcriptomic associations are hypothesis-generating, and recalibration and prospective multicenter evaluation are required before clinical application.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.